SEC and FDA Formalize Regulatory Cooperation

The U.S. Securities and Exchange Commission and the Food and Drug Administration have entered into a Memorandum of Understanding.

Official documents and a fountain pen arranged on a dark desk, lit with soft directional light creating gentle shadows.
SEC and FDA Sign MOU to Boost Market Oversight

The MOU establishes a framework for the agencies to enhance cooperation in their regulatory and enforcement responsibilities.

The agreement includes information-sharing protocols to facilitate the exchange of information between the SEC and FDA.

According to the agencies, the arrangement is designed to assist them in carrying out their respective missions of ensuring the integrity of the financial markets and protecting public health.

Highlights

  • The SEC and FDA entered into a Memorandum of Understanding (MOU).
  • The MOU establishes a framework for the agencies to enhance cooperation in their regulatory and enforcement responsibilities.
  • The agreement includes information-sharing protocols to facilitate the exchange of information between the SEC and FDA.
  • The MOU's purpose is to assist the agencies in carrying out their respective missions of ensuring the integrity of the financial markets and protecting public health.

Regulators React

SEC Chairman Paul S. Atkins commented on the announcement.

“FDA-related disclosures by public companies have a significant impact on our markets.”

Paul S. Atkins, SEC Chairman

Acting FDA Commissioner Kyle Diamantras also addressed the agreement.

“We are proud to partner with the SEC to enhance transparency across the life sciences sector.”

Kyle Diamantras, Acting FDA Commissioner